GBO extends the acceptance period in the offer for Vigmed

This announcement is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, New Zealand, South Africa or the United States or in any other jurisdictions where such offer pursuant to legislation and regulations in such relevant jurisdictions would be prohibited by applicable law. Shareholders not resident in Sweden who wish to accept the Offer (as defined below) must make inquiries concerning applicable legislation and possible tax consequences. Shareholders should refer to the offer restrictions included in the section titled “Important notice” at the end of this announcement and in the tender offer document which has been published on GBO's website for the Offer (www.gbo-vigmed.se/en/).

On 27 February 2017, Greiner Bio-One GmbH ("GBO") announced a recommended public offer to the shareholders of Vigmed Holding AB (publ) ("Vigmed") to tender all shares in Vigmed to GBO (the "Offer") for a consideration of SEK 1.00 in cash per share.

The shares tendered in the Offer at the end of the initial acceptance period on 27 March 2017 amount to in aggregate 42,709,627 shares in Vigmed, corresponding to 65.0 percent of the total number of outstanding shares and votes in Vigmed.

As previously communicated, completion of the Offer is conditional upon, inter alia, the Offer being accepted to such extent that GBO becomes the owner of more than 90 percent of all shares in Vigmed. The minimum acceptance level condition is currently not met.

To provide the shareholders in Vigmed more time to consider and to accept the Offer, GBO has, instead of withdrawing the Offer, decided to extend the acceptance period until and including 20 April 2017 at 5:00 p.m. CEST. All conditions for completion of the Offer remain unchanged. Settlement will be initiated as soon as GBO announces that the conditions for the Offer have been fulfilled or GBO otherwise decides to complete the Offer. If such announcement takes place on 25 April 2017, at the latest, settlement is expected to be initiated on or about 27 April 2017.

GBO does not currently own or control any shares in Vigmed or any financial instruments that provide a financial exposure equivalent to a holding of shares in Vigmed.

"Vigmed is in a challenging operational and critical financial situation, and the company has an immediate need of additional liquidity. Vigmed needs a strategic partner with strong financials in order to succeed in the future. We believe that GBO is the right partner for Vigmed. Our offer is fair and appealing, especially when considering the substantial capital injections that are required going forward", said Rainer Perneker, CEO of the Greiner Bio-One group.

Greiner Bio-One GmbH

For additional information, please contact:

Georg Heftberger, Chief Financial Officer, Greiner Bio-One GmbH, tel. +43 664 8841 0683

Eric Tapper, Hallvarsson & Halvarsson, tel. +46 8 407 21 80

For information and documentation regarding the Offer, please visit: www.gbo-vigmed.se/en/

This press release was submitted for publication on 30 March 2017 at 8:00 a.m. CEST.

Documents & Links